The Role of Inferior Vena Cava Filters in Cancer Patients

Mithil B. Pandhi; Kush R. Desai; Robert K. Ryu; Robert J. Lewandowski

doi:10.1055/s-0036-1581090

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2016; 33(02): 071-074
DOI: 10.1055/s-0036-1581090

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Role of Inferior Vena Cava Filters in Cancer Patients

Mithil B. Pandhi

¹Feinberg School of Medicine, Northwestern University, Chicago, Illinois

,

Kush R. Desai

¹Feinberg School of Medicine, Northwestern University, Chicago, Illinois

,

Robert K. Ryu

¹Feinberg School of Medicine, Northwestern University, Chicago, Illinois

,

Robert J. Lewandowski

²Anschutz Medical Campus, University of Colorado, Aurora, Colorado

› Author Affiliations

Abstract

Cancer induces a hypercoagulable state and renders patients susceptible to venous thromboembolism. While anticoagulation remains the mainstay of treatment, many of these patients require placement of an inferior vena cava (IVC) filter, often due to a contraindication to or failure of anticoagulation. In this article, the available data on IVC filter usage in cancer patients will be reviewed.

Keywords

IVC filters - cancer - venous thromboembolism - interventional radiology

Full Text

References

References
1 Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 2014; 8: 129-137
2 Monreal M, Lafoz E, Casals A , et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1991; 67 (2) 541-545
3 Prandoni P, Lensing AW, Büller HR , et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327 (16) 1128-1133
4 Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16 (5) 696-701
5 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12: 464-474
6 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (6) 715-722
7 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (4) 458-464
8 Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119 (1) 60-68
9 Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25 (2) 173-182
10 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19) 3665-3675
11 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6 (6) 401-410
12 Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015; 135 (Suppl. 01) S8-S11
13 Khalil J, Bensaid B, Elkacemi H , et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol 2015; 13: 204
14 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
15 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
16 Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27 (29) 4839-4847
17 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
18 Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000; 160 (22) 3431-3436
19 Prandoni P, Lensing AW, Piccioli A , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
20 Heit JA, Lahr BD, Ashrani AA, Petterson TM, Bailey KR. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res 2015; 136 (2) 298-307
21 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162) 1386-1389
22 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
23 Laporte S, Mismetti P, Décousus H , et al; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117 (13) 1711-1716
24 Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010; 363 (3) 266-274
25 Wehrenberg-Klee E, Stavropoulos SW. Inferior vena cava filters for primary prophylaxis: when are they indicated?. Semin Intervent Radiol 2012; 29 (1) 29-35
26 Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they?. Ann Oncol 2009; 20 (12) 1907-1912
27 Lee AY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
28 Hull RD, Pineo GF, Brant RF , et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
29 Meyer G, Marjanovic Z, Valcke J , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
30 Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111 (4) 270-273
31 Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7 (5) 760-765
32 Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 144-149
33 Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res 2014; 134 (1) 93-95
34 Franchini M, Bonfanti C, Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res 2015; 135 (5) 777-781
35 Smouse B, Johar A. Is market growth of vena cava filters justified? A review of indications, use, and market analysis. Endovascular Today 2010; 9 (2) 74-77
36 Stein PD, Matta F, Hull RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124 (7) 655-661
37 Kaufman JA, Kinney TB, Streiff MB , et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 2006; 17 (3) 449-459
38 Jaff MR, McMurtry MS, Archer SL , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
39 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e494S
40 Guyatt GH, Norris SL, Schulman S , et al; American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): 53S-70S
41 Kinney TB. Update on inferior vena cava filters. J Vasc Interv Radiol 2003; 14 (4) 425-440
42 Ryu RK, Lewandowski RJ. Optimizing the use of inferior vena cava filters in oncology patients: are all filters created equally?. Semin Thromb Hemost 2014; 40 (3) 401-406
43 Raman R, Leming PD, Bhandari M, Long D, Streiff MB. Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review. Oncol Rev 2010; 4 (3) 147-157
44 Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 1996; 14 (2) 652-657
45 Decousus H, Leizorovicz A, Parent F , et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338 (7) 409-415
46 Wallace MJ, Jean JL, Gupta S , et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer 2004; 101 (8) 1902-1907
47 Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002; 36 (4) 704-707
48 Narayan A, Hong K, Streiff M , et al. The impact of cancer on the clinical outcome of patients after inferior vena cava filter placement: a retrospective cohort study. Am J Clin Oncol 2014; ; [Epub ahead of print]
49 Mansour A, Ismael Y, Abdel-Razeq H. Inferior vena cava filters in patients with advanced-stage cancer. Hematol Oncol Stem Cell Ther 2014; 7 (4) 136-141
50 Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg 2006; 40 (4) 287-294
51 Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43 (6) 1111-1114
52 Lossef SV, Barth KH. Outcome of patients with advanced neoplastic disease receiving vena caval filters. J Vasc Interv Radiol 1995; 6 (2) 273-277
53 Duszak Jr R, Parker L, Levin DC, Rao VM. Placement and removal of inferior vena cava filters: national trends in the Medicare population. J Am Coll Radiol 2011; 8 (7) 483-489
54 Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013; 173 (7) 513-517
55 Peterson EA, Yenson PR, Liu D, Lee AY. Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. Thromb Res 2014; 134 (2) 300-304
56 Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. J Vasc Interv Radiol 2014; 25 (8) 1181-1185
57 Vijay K, Hughes JA, Burdette AS , et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. J Vasc Interv Radiol 2012; 23 (2) 188-194
58 Nicholson W, Nicholson WJ, Tolerico P , et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010; 170 (20) 1827-1831
59 Minocha J, Idakoji I, Riaz A , et al. Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol 2010; 21 (12) 1847-1851
60 Eifler AC, Lewandowski RJ, Gupta R , et al. Optional or permanent: clinical factors that optimize inferior vena cava filter utilization. J Vasc Interv Radiol 2013; 24 (1) 35-40
61 Mikhail S, Hannan L, Pishvaian MJ, Kessler C. Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial?. Med Oncol 2015; 32 (6) 622
62 Abtahian F, Hawkins BM, Ryan DP , et al. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med 2014; 127 (11) 1111-1117